Will Teva's Deal With AstraZeneca Over Nexium Patents Erode Ranbaxy's Marketing Exclusivity In 2014?

MUMBAI - Teva's patent dispute settlement with AstraZeneca for a delayed launch of generic copies of the blockbuster heartburn drug brand Nexium (esomeprazole) led to enormous confusion and panic among Indian stock market investors regarding the status of Ranbaxy's 180-day sole marketing exclusivity for the drug starting May 2014